This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
